KindredBio Announces Appointment of Stephen Sundlof, Former Director of FDA’s CVM, as Senior Vice President of Regulatory Affairs

/in , , /by

SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.

Read more

KindredBio Announces Initiation of Pivotal Clinical Study for CereKin™

/in , , /by

CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.

SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of CereKin™ by 2015.

Read more